{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:01:56Z","timestamp":1740106916490,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the grants from the Science and Technology Innovation Base Construction Project of Jiangxi Province","award":["20212BCG74001","20212BCG74001","20212BCG74001","20212BCG74001"],"award-info":[{"award-number":["20212BCG74001","20212BCG74001","20212BCG74001","20212BCG74001"]}]},{"DOI":"10.13039\/501100001809","name":"the National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["No:82060030","No:82070132","No:82060030"],"award-info":[{"award-number":["No:82060030","No:82070132","No:82060030"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Trainingthe Project of Major Leaders for Academic and Technical in Jiangxi Province","award":["20213BCJ22016","20213BCJ22016","20213BCJ22016","20213BCJ22016","20213BCJ22016"],"award-info":[{"award-number":["20213BCJ22016","20213BCJ22016","20213BCJ22016","20213BCJ22016","20213BCJ22016"]}]},{"name":"the key projects for scientific and technological cooperation of Jiangxi Province","award":["2021BDH80024","2021BDH80024","2021BDH80024"],"award-info":[{"award-number":["2021BDH80024","2021BDH80024","2021BDH80024"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic neutrophil leukemia (CNL) is a rare and life-threatening disease. Cases of CNL combined with lymphoma are rare. Here, we report a case of CNL with T-acute lymphoblastic leukemia\/lymphoma (T-ALL\/LBL) in a 28-year-old male. After a regimen of ruxolitinib, VICLP (Vincristine, Idarubicin, Cyclophosphamide, Prednisone, Peg-asparaginase) regimen, high-dose cytarabine, and methotrexate regimens, the patient\u2019s bone marrow condition partially resolved. However, when the disease relapsed four months later, despite attempts with selinexor, venetoclax, and CAG(aclarubicin hydrochloride, Algocytidine, Granulocyte Stimulating Factor) chemotherapy, the leukocytes and peripheral blood primitive cells reduced, but the bone marrow did not achieve remission. This pathogenesis may be related to microenvironmental immune escape under prolonged inflammatory stimulation and gene disruption affecting protein function due to colony-stimulating factor 3 receptor gene (CSF3R) mutations. For this type of disease, early intervention may delay disease progression.<\/jats:p>","DOI":"10.1007\/s00277-024-05759-z","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T05:02:19Z","timestamp":1722920539000},"page":"4319-4323","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rare case of simultaneous occurrence of chronic neutrophil leukemia and T lymphoblastic lymphoma: case report and literature review"],"prefix":"10.1007","volume":"103","author":[{"given":"Shi-xuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye-chao","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-lan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song-tao","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie-yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke-bing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"5759_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41408-018-0058-7","volume":"8","author":"N Szuber","year":"2018","unstructured":"Szuber N, Finke CM, Lasho TL, Elliott MA, Hanson CA, Pardanani A, Tefferi A (2018) CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. Blood Cancer J 8:21. https:\/\/doi.org\/10.1038\/s41408-018-0058-7","journal-title":"Blood Cancer J"},{"key":"5759_CR2","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","volume":"368","author":"JE Maxson","year":"2013","unstructured":"Maxson JE, Gotlib J, Pollyea DA et al (2013) Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 368:1781\u20131790. https:\/\/doi.org\/10.1056\/NEJMoa1214514","journal-title":"N Engl J Med"},{"key":"5759_CR3","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1038\/leu.2013.122","volume":"27","author":"A Pardanani","year":"2013","unstructured":"Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson RA, Ketterling RP, Maxson JE, Tyner JW, Tefferi A (2013) CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 27:1870\u20131873. https:\/\/doi.org\/10.1038\/leu.2013.122","journal-title":"Leukemia"},{"key":"5759_CR4","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1182\/blood.2019000611","volume":"134","author":"H Zhang","year":"2019","unstructured":"Zhang H, Wilmot B, Bottomly D et al (2019) Genmic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood 134:867\u2013879. https:\/\/doi.org\/10.1182\/blood.2019000611","journal-title":"Blood"},{"key":"5759_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s12885-018-4236-6","volume":"18","author":"XB Wu","year":"2018","unstructured":"Wu XB, Wu WW, Zhou Y, Wang X, Li J, Yu Y (2018) Coexisting of bone marrow fibrosis, dysplasia and an X chromosomal abnormality in chronic neutrophilic leukemia with CSF3R mutation: a case report and literature review. BMC Cancer 18:343. https:\/\/doi.org\/10.1186\/s12885-018-4236-6","journal-title":"BMC Cancer"},{"key":"5759_CR6","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3324\/haematol.2010.033779","volume":"96","author":"E Rumi","year":"2011","unstructured":"Rumi E, Passamonti F, Elena C, Pietra D, Arcaini L, Astori C, Zibellini S, Boveri E, Pascutto C, Lazzarino M (2011) Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. Haematologica 96:454\u2013458. https:\/\/doi.org\/10.3324\/haematol.2010.033779","journal-title":"Haematologica"},{"key":"5759_CR7","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/ajh.25049","volume":"93","author":"M Marchetti","year":"2018","unstructured":"Marchetti M, Carobbio A, Capitoni E, Barbui T (2018) Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: a systematic review. Am J Hematol 93:698\u2013703. https:\/\/doi.org\/10.1002\/ajh.25049","journal-title":"Am J Hematol"},{"key":"5759_CR8","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1182\/blood-2017-10-810739","volume":"132","author":"E Porpaczy","year":"2018","unstructured":"Porpaczy E, Tripolt S, Hoelbl-Kovacic A et al (2018) Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy. Blood 132:694\u2013706. https:\/\/doi.org\/10.1182\/blood-2017-10-810739","journal-title":"Blood"},{"key":"5759_CR9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787\u2013798. https:\/\/doi.org\/10.1056\/NEJMoa1110556","journal-title":"N Engl J Med"},{"key":"5759_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00277-016-2884-7","volume":"96","author":"M Breccia","year":"2017","unstructured":"Breccia M, Andriani A, Montanaro M et al (2017) Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN. Ann Hematol 96:387\u2013391. https:\/\/doi.org\/10.1007\/s00277-016-2884-7","journal-title":"Ann Hematol"},{"issue":"6","key":"5759_CR11","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/ajh.26026","volume":"96","author":"PL Mouchel","year":"2021","unstructured":"Mouchel PL, Syrykh C, Laurent C, Tavitian S, Gauthier M (2021) First case of classical Hodgkin-like EBV-positive lymphoproliferative disorder under ruxolitinib therapy. Am J Hematol 96(6):755\u2013756. https:\/\/doi.org\/10.1002\/ajh.26026","journal-title":"Am J Hematol"},{"issue":"21","key":"5759_CR12","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1182\/blood-2019-03-900951","volume":"133","author":"E Rumi","year":"2019","unstructured":"Rumi E, Zibellini S (2019) JAK inhibitors and risk of B-cell lymphomas. Blood 133(21):2251\u20132253. https:\/\/doi.org\/10.1182\/blood-2019-03-900951","journal-title":"Blood"},{"issue":"21","key":"5759_CR13","doi-asserted-by":"publisher","first-page":"5389","DOI":"10.1182\/bloodadvances.2020003109","volume":"4","author":"CS Boddy","year":"2020","unstructured":"Boddy CS, Tan BT, Aoki J (2020) B-lymphoblastic leukemia arising in a patient with chronic neutrophilic leukemia. Blood Adv 4(21):5389\u20135392. https:\/\/doi.org\/10.1182\/bloodadvances.2020003109","journal-title":"Blood Adv"},{"key":"5759_CR14","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1074\/jbc.M113.508440","volume":"289","author":"JE Maxson","year":"2014","unstructured":"Maxson JE, Luty SB, MacManiman JD, Abel ML, Druker BJ, Tyner JW (2014) Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization. J biol chem 289:5820\u20135827. https:\/\/doi.org\/10.1074\/jbc.M113.508440","journal-title":"J biol chem"},{"issue":"8","key":"5759_CR15","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/leu.2016.376","volume":"31","author":"S Rohrabaugh","year":"2017","unstructured":"Rohrabaugh S, Kesarwani M, Kincaid Z et al (2017) Enhanced MAPK signaling is essential for CSF3R-induced leukemia. Leukemia 31(8):1770\u20131778. https:\/\/doi.org\/10.1038\/leu.2016.376","journal-title":"Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05759-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05759-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05759-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T09:05:46Z","timestamp":1729933546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05759-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["5759"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05759-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"assertion":[{"value":"19 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors consent to publish.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third-party material in this article are included in the article\u2019s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article\u2019s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit .","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Open Access"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}